Navigation Links
Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
Date:11/11/2013

temprop="name">Susan McElroy, MD; Research Institute, Lindner Center of HOPE, Mason, OH, USA.
Title: Naltrexone/bupropion is associated with early and longer-term improvement in binge eating disorder that is related to improvement in depression

About Contrave
About Contrave (32 mg naltrexone sustained‐release (SR)/360 mg bupropion SR) being evaluated for the treatment of obesity: In 2012, Orexigen enrolled more than 10,400 with approximately 8900 randomized patients in the Light Study. The primary objective of the double‐blind, randomized, placebo‐controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the U.S. Food and Drug Administration (FDA), is to assess the occurrence of major adverse cardiovascular events in overweight and obese patients receiving Contrave. An interim analysis of the Light Study is anticipated by early December, enabling the potential resubmission of the Contrave New Drug Application to the FDA by year end.

In October, Orexigen submitted a Marketing Authorization Application for Contrave to the European Medicines Agency.

Orexigen has licensed North American Contrave commercial rights to Takeda Pharmaceuticals. Orexigen owns Contrave rights in Europe and throughout the rest of the world outside of North America and will seek a partner to commercialize Contrave in those territories.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a NDA has been submitted and reviewed by the FDA. The company has also reached agreement with the FDA on a SPA for the Light Study, the Contrave cardiovascular outcomes trial. The company's other product candidate, Empatic, has completed Phase 2 clinical t
'/>"/>

SOURCE Orexigen Therapeutics, Inc.; Takeda Pharmaceuticals, U.S.A., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 By now, if you haven,t heard about ... this planet. The awareness campaign has brought this devastating disease ... raise over $88.5 Million (and counting) for ALS. Every day, ... are starting to as well. One such company, ... , who actually works with ALS sufferers and helps to ...
(Date:8/27/2014)...  Hill-Rom Holdings, Inc. (NYSE: HRC ) ... the Morgan Stanley Global Healthcare Conference on September 8, ... invited to listen to the live discussion via the ... directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP .  A recorded replay of ... of the live event and accessible at the links ...
(Date:8/27/2014)... Mass. , Aug. 27, 2014 North American ... a prestigious R&D 100 Award for the new OSRAM ITOS ... and LED-based white light module for microscopy, endoscopy and surgical ... lamps with significantly higher efficacy and lamp life. ... as one of the most innovative new technologies of the ...
Breaking Medicine Technology:Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3
(Date:8/27/2014)... August 28, 2014 All Canada Goose ... they can go from classic to modern. With unique detailing ... each of them is a step up in opulence. Recently, ... Goose Banff Parkas for 2014. , True enough, ... now offering great discounts (up to 28% off) on all ...
(Date:8/27/2014)... Today, Zane Benefits, the #1 Online ... for administering a premium reimbursement plan. , According ... compliance is top of mind for employers, health insurance ... insurance and premium reimbursement, there are important compliance considerations ... minute webinar, Zane Benefits President, Rick Lindquist, will cover ...
(Date:8/27/2014)... CA (PRWEB) August 27, 2014 Locating ... require a consumer to present personal information before rates ... the way that life insurance quotes are distributed online ... , The term plans that an adult has access ... by known U.S. companies. The system for quotation distribution ...
(Date:8/27/2014)... August 28, 2014 Recently, iFitDress.com, a ... announced its new designs of romantic bridal gowns ... enjoy a promotional price (up to 66 percent off) ... the company’s product line has been updated with these ... and patient. iFitDress.com hopes that all clients can gain ...
(Date:8/27/2014)... 2014 The American College ... the management and treatment of pulmonary arterial hypertension ... Hypertension in Adults: CHEST Guideline, in the journal ... clinicians, and provide the latest and most accurate ... Hypertension Association (PHA) – the country’s leading ...
Breaking Medicine News(10 mins):Health News:CanadaGooseJackor.nu: 2014 Canada Goose Banff Parkas At Discounted Prices 2Health News:Zane Benefits Announces Upcoming Webinar on Compliance 2Health News:Life Insurance Quotes for Term Policies Now Found at Insurer Website Online 2Health News:Promotion For Romantic Bridal Gowns Launched By Professional Company iFitDress.com 2Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2
... perspective, it may be more efficient to use the drug ... wild-type KRAS gene, according to a study published online August ... . Earlier, patients whose tumors harbored wild-type KRAS were ... cetuximab in a randomized trial by the National Cancer Institute ...
... BEIJING, Aug. 7 /PRNewswire-Asia-FirstCall/ -- China ... ), a leading China-based medical device,company that develops, ... the appointment of PricewaterhouseCoopers ("PwC") as,the Company,s independent ... independent auditors, KPMG. , ...
... , , , Senate ... Care Bill , , WASHINGTON, Aug. 7 ... Senate Finance Committee to reject a provision imposing a 20% co-pay ... to the American health care system, this provision would shift billions ...
... , , MORRISTOWN, N.J., Aug. ... leading specialty pharmaceutical company, announced today that one lot of 100 ... being voluntarily recalled from wholesalers and pharmacies. The recalled patches ... and were manufactured by Watson Laboratories, Inc. and distributed by Watson ...
... , NEW YORK, Aug. 7 Duane ... results of the previously announced offers by its wholly-owned subsidiaries, ... purchase for cash (i) any and all of the Issuers, ... Rate Notes due 2010 (the "Floating Rate Notes") (the "FRN ...
... early risk factors and patterns of development , FRIDAY, ... as second grade for symptoms of depression may help ... University of Washington study shows. , Even though ... never developed more than a few symptoms of depression, ...
Cached Medicine News:Health News:Cost-effectiveness of cetuximab in metastatic colorectal cancer 2Health News:China Medical Technologies Announces Change of Independent Auditors 2Health News:Seniors: Get Your Checkbooks Ready 2Health News:Watson Announces Limited Recall Of Fentanyl Transdermal System 2Health News:Watson Announces Limited Recall Of Fentanyl Transdermal System 3Health News:Duane Reade Holdings, Inc. Announces Expiration and Results of Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures 2Health News:Duane Reade Holdings, Inc. Announces Expiration and Results of Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes and Solicitation of Consents to Related Indentures 3Health News:Signs of Depression Noted in Second Graders 2
Inoculum Broth...
Inoculum Broth with Calcium Chloride and Phytone....
... ready-to-use solutions ideal for a wide range ... prepared with 18 megOhm water, filtered using ... sterile bottles., Reliable - Manufactured according ... lot-to-lot consistency. , High Quality - ...
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
Medicine Products: